A dose finding design for seizure reduction in neonates

Moreno Ursino, Ying Yuan, Corinne Alberti, Emmanuelle Comets, Geraldine Favrais, Tim Friede, Frederike Lentz, Nigel Stallard, Sarah Zohar

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Clinical trials in vulnerable populations are extremely difficult to conduct. A sequential phase I–II trial aimed at finding the appropriate dose of levetiracetam for treating neonatal seizures was planned with a maximum sample size of 50 newborns. Three primary outcomes are considered: efficacy and two types of toxicity that occur at the same time but are measured at different time points. In the case of failure, physicians could add a second agent as a rescue medication. The primary outcomes were modelled via a logistic model for efficacy and a weighted likelihood with pseudo-outcomes for the two toxicities taking into account the dependences under Bayesian inference. Simulations were conducted to assess the design properties.

Original languageEnglish (US)
Pages (from-to)427-444
Number of pages18
JournalJournal of the Royal Statistical Society. Series C: Applied Statistics
Volume68
Issue number2
DOIs
StatePublished - Feb 1 2019

Keywords

  • Efficacy
  • Newborns
  • Phase I–II
  • Time to event
  • Toxicity constraints

ASJC Scopus subject areas

  • Statistics and Probability
  • Statistics, Probability and Uncertainty

Fingerprint

Dive into the research topics of 'A dose finding design for seizure reduction in neonates'. Together they form a unique fingerprint.

Cite this